Wednesday, September 20, 2017
Company News: Page (1) of 1 - 05/19/17 Email this story to a friend. email article Print this page (Article printing at page facebook
Global Crohn's Disease Market and Forecast Analysis 2017-2035: Number of Prevalent Cases of Crohn's Disease is Expected to Increase by 16.9% to 1.6 Million over 2015-35 - Research and Markets
(May 19, 2017)

DUBLIN, May 19, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Crohn's Disease Market and Forecast Analysis" report to their offering.

Research and Markets Logo

Crohn's disease involves inflammation of the gastrointestinal (GI) tract and most commonly affects the terminal ileum or colon. Because Crohn's disease can occur in various areas of the GI tract, disease activity and severity can vary widely over time, with symptoms ranging from mild to severe and depending on the location in the GI tract at which the disease is active. Crohn's disease is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood.

Crohn's disease is currently an idiopathic condition, the pathogenesis of which is yet to be fully elucidated. However, it is known to involve an interaction between genetics, the immune system, and environmental factors. Risk factors include ethnicity, smoking, family history, antibiotic or non-steroidal anti-inflammatory agent use, and diet.

It is estimated that in 2015, there were 1.4 million diagnosed prevalent cases of Crohn's disease in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Over 2015-35, the number of prevalent cases is expected to increase by 16.9% to 1.6 million.

Key Topics Covered:

1. Treatment: Crohn's Disease

  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends
  • Compliance
  • Unmet Needs in Crohn's Disease
  • Prescribing Influences
  • Impact of Biosimilars

2. Epidemiology: Crohn's Disease

  • Disease Background
  • Sources and Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations

3. Marketed Drugs: Crohn's Disease

  • Product profile: Cimzia
  • Product profile: Entyvio
  • Product profile: Humira
  • Product profile: Pentasa
  • Product profile: Remicade
  • Product profile: Tysabri

4. Pipeline: Crohn's Disease

  • Executive Summary
  • Clinical Pipeline Overview

For more information about this report visit

Media Contact:

Laura Wood, Senior Manager
[email protected] 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


To view the original version on PR Newswire, visit:

SOURCE Research and Markets

Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords:Diet, Disease, Surgery, Science, Medical, Biology, Genetics, Family,
Related Sites: HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines